Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12858462 | 0.86 | JAK2 (0.53) | TAS1R3TAS1R1SMN1; SMN2ATMTDP1 | |
| SCHEMBL1588987 | 0.82 | EPHX1 (0.56) | TAS1R3TAS1R1EPHX1SMN1; SMN2TDP1 | |
| SCHEMBL23479840 | 0.81 | TAS1R3 (0.53) | TAS1R3TAS1R1EPHX1SMN1; SMN2TDP1 | |
| SCHEMBL23479839 | 0.81 | TAS1R3 (0.53) | TAS1R3TAS1R1EPHX1SMN1; SMN2TDP1 | |
| SCHEMBL16648601 | 0.76 | EPHX1 (0.81) | TAS1R3TAS1R1EPHX1SMN1; SMN2TAS1R2 | |
| SCHEMBL25689275 | 0.75 | EPHX1 (0.61) | TAS1R3TAS1R1EPHX1SMN1; SMN2TAS1R2 | |
| SCHEMBL11067027 | 0.75 | ATM (0.73) | EPHX1SMN1; SMN2ATM | |
| SCHEMBL23772197 | 0.74 | EPHX1 (0.60) | TAS1R3TAS1R1EPHX1SMN1; SMN2TAS1R2 | |
| SCHEMBL23573438 | 0.74 | EPHX1 (0.60) | TAS1R3TAS1R1EPHX1SMN1; SMN2TAS1R2 | |
| SCHEMBL23573200 | 0.74 | EPHX1 (0.60) | TAS1R3TAS1R1EPHX1SMN1; SMN2TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760733-B2 | Small molecule regulators of mitochondrial fusion and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| US-10844023-B2 | Small molecule regulators of mitochondrial fusion and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200281899-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| US-20190169138-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| WO-2018200323-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169138-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | MFN2, FIS1, RHOT2 | TAS1R3 4410/4885TAS1R1 4241/4885EPHX1 4385/4885 |
| US-11760733-B2 | Small molecule regulators of mitochondrial fusion and methods of use thereof | MFN2, FIS1, RHOT2 | TAS1R3 4410/4885TAS1R1 4241/4885EPHX1 4385/4885 |
| US-20200281899-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | MFN2, FIS1, RHOT2 | TAS1R3 4410/4885TAS1R1 4241/4885EPHX1 4385/4885 |
| US-10844023-B2 | Small molecule regulators of mitochondrial fusion and methods of use thereof | MFN2, FIS1, RHOT2 | TAS1R3 4410/4885TAS1R1 4241/4885EPHX1 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.